Researchers edge closer to hep C cure
A combination of pills – one still in the experimental phase and another recently approved for the US market – are effective in hepatitis C, according to new research.
However, the cost of the treatment is expected to be at least $A89,490 per year, experts have said.
The New England Journal of Medicine published the latest data from a phase II clinical trial on daclatasvir and sofosbuvir.
Sofosbuvir was approved by the US Food and Drug Administration in December and has been given the brand name